J. John Mann, MD

There has been much debate about whether certain classes of medications (eg, antidepressants) increase the risk of suicidal behavior and whether that risk is greater in children, adolescents, and young adults. In 2004, the FDA placed a black box warning on all antidepressants because of concerns that the medications increase risk of suicidal thoughts and behavior in youths; in 2006, the warning was extended to include young adults (up to age 26). The FDA based its black box warning on results of its meta-analyses of randomized controlled trials (RCTs) conducted in pediatric and adult psychiatric and nonpsychiatric populations.

Questions regarding a possible relationship between antidepressants and suicide were first raised in 1990 with the publication of a series of case reports in which the then newly introduced SSRIs were associated with the apparent emergence of suicidal thoughts and behavior.

 This led to FDA hearings in 1991, but no evidence of an increased risk of suicidal acts associated with antidepressants was found. In October 2004, concerns raised over paroxetine use in children and adolescents eventually led the FDA to issue a black box warning regarding antidepressants and suicide for children younger than 18 years.

The evidence supporting the first black box warning came from a meta-analysis that combined spontaneous reports of suicidal thoughts and behaviors from pediatric RCTs of newer antidepressants, mostly SSRIs.

 The risk of suicidal ideation and behavior, or suicidality, was found to be higher for children treated with antidepressants than for those given placebo (odds ratio [OR] = 1.78; 95% confidence interval [CI], 1.14, 2.77). The FDA also presented results of an analysis of prospective data (suicidal ideation or behavior rating-scale item) that showed no effect for emergence (OR: 0.93; 95% CI: 0.75, 1.15) or emergence and/or worsening of suicidal thoughts and behavior in the active-drug group compared with the placebo group (OR = 0.92; 95% CI, 0.76, 1.11).

The inconsistency between the prospective clinician ratings and spontaneous patient reports has not been adequately explained. It may be due to bias because patients randomized to active drug treatment have a greater likelihood of adverse effects in general, leading to more contact or conversation with study staff and increased chance of having any suicidal thoughts observed. Similarly, overdose on study medication is more likely to be reported if it results in the need for medical attention, as would be true for patients who receive active treatment rather than placebo.

Systematic questioning in a setting such as the emergency department or inpatient service generally gives a more accurate rate of suicidal ideation and behavior than do spontaneous reports. The FDA based its decision on the “signal” of risk from spontaneous adverse-event reports and not on the absence of a signal of risk from systematic clinician evaluations.

In January 2006, the FDA conducted a second meta-analysis of 372 RCTs of newer antidepressants in an adult population of approximately 100,000 patients.

 This analysis was based on spontaneous adverse-event reports from the RCTs and did not provide data from prospective clinician ratings. Overall, the analysis revealed no evidence of more suicide-related adverse reports in the antidepressant group than in the placebo group. Stratification by age showed that for the primary endpoint of suicidal ideation or behavior, for 18- to 24-year-olds, the risk was increased with medication compared with placebo, and the risk approached significance (OR = 1.62; 95% CI, 0.97, 2.71); for adults aged 25 to 64 years, the risk was significantly decreased (OR = 0.79; 95% CI, 0.64, 0.98); and for geriatric patients, the risk was markedly decreased (OR = 0.37; 95% CI, 0.18, 0.76) with antidepressants relative to placebo. On the basis of these results, the FDA extended the black box warning to cover 18- to 24-year-olds.

Since the FDA warnings, studies have been conducted to explore the relationship between initiation of antidepressant treatment and suicidal events. We review several lines of evidence that range from the weakest data based on spontaneous reports to the most rigorous data based on RCTs.

 Spontaneous reports to the FDA can be made by anyone; most are from patients, physicians, pharmaceutical companies, and plaintiff attorneys. They report both an adverse event and a listing of one or more medications that a patient is taking at the time of the event. Use of the spontaneous reporting systems for drug safety determination is highly problematic. Some limitations regarding these data are:

• Confounding by indication (ie, patients taking a particular drug may have a disease that is itself associated with a higher incidence of the adverse event)

• Effects of publicity in the media on numbers of reports

• Attribution of the event to a single drug when patients may be taking multiple drugs

These limitations degrade the capacity for optimal data mining and analysis, and any conclusions must be tentative and require validation by another data source.

Data from the FDA Adverse Event Reporting System (MedWatch) from 1998 to 2004 for all antidepressants and completed suicide were analyzed by our group.

 The dataset comprised a total of 28,317,382 records, including all reported adverse events and drug combinations. A national prescription rate for each antidepressant by year is the denominator in the analysis. 

 presents a plot of the estimated rate multipliers and confidence limits for each drug. As a class, both SSRIs and SNRIs have rate multipliers that are significantly less than 1.0 (ie, lower than the national average suicide adverse-event report rate for antidepressants as a class). By contrast, TCAs have rate multipliers that are significantly above the national average suicide rate for antidepressants. TCAs have a significantly higher risk of suicide adverse-event reports than do SSRIs and SNRIs.

This is striking because one might anticipate an increase in reports related to SSRIs given the highly publicized concern over a possible link between suicide and the use of SSRIs. However, TCAs are much more toxic than SSRIs on overdose and are much more likely to produce a medically serious outcome. Therefore, it may be important to separate reports of medically serious overdoses using TCAs or SSRIs. Comparing the incidence of other types of suicide-related reports for these classes of medication may clarify the situation.

. For very rare events, such as those that occur at rates of 1 in 10,000 or less (eg, death by suicide), there are few options for routine drug surveillance because very large populations of patients are needed to detect enough events to be informative. One approach is to use ecological data that relate changes in drug prescription rates to suicide rates in large populations.

Decreases in suicide rate over time have been shown to correlate with increased antidepressant use in many studies around the world, including those in Europe, Scandinavia, the US, and Australia. In Sweden, the doubling of prescriptions for SSRIs correlated with a 25% decrease in the suicide incidence.

 In an analysis of 27 countries, Ludwig and Marcotte

 showed that an increase of 1 pill per capita (a 13% increase over 1999 levels) was associated with a 2.5% reduction in suicide rates, a relationship that was more pronounced in adults than in children.

Japan is a curious anomaly. Researchers there found a positive association between suicide rates and antidepressant prescriptions.

 clearly shows an overall positive association between SSRI prescriptions and suicide rates; however, stratification by age reveals that within each age stratum, an inverse association is observed. This is a classic illustration of Simpson’s paradox. What it indicates is that in Japan, both suicide rates and use of antidepressants increase with age; however, for a given age-group, suicide rates have decreased with increasing SSRI prescriptions over time.

Another anomaly is Iceland, where antidepressant prescription rates seemed unrelated to lower suicide rates. Part of the reason for this are the traditionally extremely low suicide rates in Iceland. This is a floor effect; there is so little room for a further decline in suicide rates that the relationship to prescription rates is extremely hard to detect. Italy has had a decline in suicide rates linked to prescriptions for women but not for men. Most antidepressants in Italy are prescribed for women, and so the ability to detect such a relationship is greater in women.

Ecological modeling from large numbers of small areas can also provide a stronger basis for understanding the association between antidepressant medication use and suicide completion. US county-level data on suicide rates and antidepressant prescription rates were analyzed for 1996 to 1998.

 After adjusting for sex, race, age, income, and unobservable county-level effects, the analyses revealed that increases in SSRI and SNRI prescriptions were associated with decreases in suicide rates both between and within counties over time. Conversely, counties with higher rates of TCA prescriptions were associated with higher suicide rates; this may be because of the greater toxicity of this class of agents and/or their more frequent use in areas with poorer access to quality mental health services. This finding has been replicated in children and young adolescents (aged 5 to 14 years) and indicates that the relationship is robust and manifest across the life cycle, from childhood to adulthood.

 examined the effects of antidepressants on 24,119 adolescents with a first diagnosis of major depression. At least 6 months of follow-up data were available, which showed that treatment with SSRIs, other antidepressants, or combinations of antidepressants did not increase the risk of suicide attempts. Similar results were seen by Simon and colleagues.

 conducted a case-control study in depressed children and found a significant association for both suicide attempts (n = 263) and suicide completion (n = 8) in children treated with antidepressants. Tiihonen and colleagues

 found that current antidepressant use was associated with increased risk of suicide attempts but lower risk of suicide completion in youths who had been treated with an antidepressant.

A cohort study of 226,866 veterans with newly diagnosed depression indicated that the attempted suicide rate was lower in those treated with only an SSRI (monotherapy) than in those who did not receive an antidepressant (123/100,000 vs 335/100,000, respectively; OR = 0.37; 95% CI, 0.29, 0.47).

 In SSRI-treated patients, the rate of suicide attempts was lower after treatment (123/100,000) than before treatment (221/100,000; relative risk = 0.56; 95% CI, 0.44, 0.71). Analyses stratified by age showed that the benefit for 18- to 24-year-olds was comparable to that for the older age-groups: this contrasts with the FDA findings of greater risk in young adults that prompted the extension of the black box warning to include this age-group.

These data have been reanalyzed using discrete-time survival analysis and showed a robust decrease in suicide attempt rate with SSRI monotherapy (hazard ratio = 0.17; 95% CI, 0.10, 0.28).

, the incidence of attempted suicide decreased concurrently with time from the index episode, and the hazard rate was much lower for treated patients during the first few months following treatment initiation; however, the difference becomes indistinguishable by 9 months following the index episode. The lack of detectable benefit 9 months later may reflect a combination of spontaneous remission of major depression in the placebo group and declining compliance over time with treatment in the medicated group.

 analyzed an expanded set (27 studies) of pediatric RCTs of antidepressant treatment and suicidality and found less correlation between the two than the FDA’s original findings. Their report used a larger data set than the FDA’s and found a more favorable risk to benefit ratio.

In our research synthesis of longitudinal data, fluoxetine in youths, adults, and the elderly and venlafaxine in adults were shown to be efficacious in all age-groups. Children experienced the maximum benefit and the elderly only marginal benefit following 6 weeks of treatment.

 Adults and the elderly had significant benefit from antidepressant treatment in terms of reduction of suicidal thoughts and behavior; however, this improvement was mediated by a decrease in depressive severity. 

 reveals that over time in both treated and control patients, there was a decrease in the frequency of suicidal thoughts and behavior; however, the decrease was significantly more pronounced in patients randomized to antidepressant treatment.

The magnitude of the difference between active treatment and control in terms of suicidal thoughts and behavior increases over time in adults and the elderly; however, there was no effect of treatment on suicidal thoughts and behavior in children, despite statistically and clinically significant benefits in terms of depression observed with active treatment. These findings suggest that suicidal thoughts and behavior in adults are largely driven by depression severity; however, this does not appear to be the case for children.

Clinicians who treat adults need to focus on maximizing the degree of improvement in depression to maximize the decrease in suicidal ideation and thereby acute suicide risk. These findings are consistent with a recent report in which most suicidal adolescents (more than 80%) received some form of mental health treatment, but such treatment failed to prevent suicidal behavior from occurring.

What happened following the black box warning?

Ecological studies revealed that there may have been unintended consequences of the black box warning. Evidence now shows that antidepressant prescription rates dropped precipitously beginning with the public health advisory in March 2004, which preceded the black box warning in October 2004. Since the initial public health advisory, antidepressant prescriptions for children and adolescents decreased, with a consequent increase (14%) in incidence of suicide in these populations.

 No increase in suicide was found in the elderly, for whom antidepressant prescription rates continued to increase.

 found significant decreases in the number of new cases of child and young adult depression that were diagnosed by general practitioners following the black box warning (44% reduction in pediatric patients and 37% in young adults). Isacsson and Ahlner26 looked at 845 suicides in the 10- to 19-year-old group in Sweden from 1992 through 2010. After the 2004 warning, the suicide rate increased for 5 consecutive years (60.5%), largely in those who were not treated with antidepressants.

 studied academic and behavioral outcomes in more than 100,000 adolescents aged 12 to 17 using a difference-in-difference design. They found that grade point averages (GPAs) for depressed children decreased 0.20 points following the black box warning in the US; however, there was no change in GPAs in non-depressed children. They also found increases in delinquency and use of tobacco and illicit drugs among depressed adolescents.

The FDA implementation of a black box warning had the purpose of reducing suicide rates in children, adolescents, and young adults. The picture following the FDA warning and implementation of the black box warning is not that of a lower suicide rate as intended or hoped for by the FDA. Instead, we see fewer antidepressant prescriptions, an increase in youth suicides, and negative effects on human capital. That outcome is difficult to reconcile with a model of an increase in youth suicide risk when antidepressants are prescribed. The findings fit better with a model of a net reduction in suicide risk when antidepressants are prescribed.

The data show that in adults, antidepressants appear to protect against suicidal events. SSRIs are associated with lower overall suicide rates compared with other classes of antidepressants (eg, TCAs). Antidepressants are effective in reducing symptoms, which, in turn, mediates suicidal events in adults and the elderly. This does not appear to be the case for youths, for whom antidepressant medications can reduce the severity of depression but appear to have no effect one way or the other on suicidal thoughts and behavior. Conversely to what is seen in adults, it may be that aggressive-impulsive traits play a more important role in youth suicide than does depressed mood. The impact of antidepressants on these traits remains unclear. Youth suicide may also be potentially related to illicit drug use and social factors, such as bullying, that are not directly affected by antidepressants.

The black box warning and the earlier public health advisory have shown that discouraging the medication treatment of depression in children is not an effective solution in preventing suicidal behavior. Careful monitoring and treatment of depression and monitoring suicide risk in children is clearly essential. Overall, the clinical evidence is that the majority of patients, young and old, benefit from antidepressants, without increased risk of suicide.

Ten years after the introduction of the black box warning, it is time that the FDA reevaluates this decision and that the results be made public. Moreover, the labeling language should be rewritten to clearly delineate the risks of treatment compared with the risks of no treatment.

Dr Gibbons is Professor of Biostatistics in the departments of medicine, public health sciences, and psychiatry, and Director of the Center for Health Statistics at the University of Chicago. Dr Mann is the Paul Janssen Professor of Translational Neuroscience in the department of psychiatry at Columbia University, and Director, Molecular Imaging and Neuropathology Division, the New York State Psychiatric Institute, New York. The authors report no conflicts of interest concerning the subject matter of this article.

 Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. 

 Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. 

 Food and Drug Administration. Clinical review: relationship between antidepressant drugs and suicidality in adults. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf. Accessed November 5, 2014.

 Hauben M, Riech L, DeMicco J, Kim K. ‘Extreme duplication’ in the US FDA adverse events reporting system database. 

 Gibbons RD, Segawa E, Karabatsos G, et al. Mixed-effects Poisson regression analysis of adverse event reports: the relationship between antidepressants and suicide. 

 Isacsson G. Suicide prevention-a medical breakthrough? 

 Ludwig J, Marcotte DE. Anti-depressants, suicide, and drug regulation. 

 Nakagawa A, Grunebaum MF, Ellis SP, et al. Association of suicide and antidepressant prescription rates in Japan, 1999-2003. 

 Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. 

 Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. 

 Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. 

 Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. 

 Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. 

 Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. 

 Tiihonen J, LÃ¶nnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. 

 Gibbons RD, Brown CH, Hur K, et al. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. 

 Gibbons RD, Amatya AK, Brown CH, et al. Post-approval drug safety surveillance. 

 Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. 

 Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. 

 Gibbons RD, Brown CH, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine [published correction appears in Arch Gen Psychiatry. 2013;70:881]. 

 Nock MK, Green JG, Hwang I, et al. Prevalence, correlates, and treatment of lifetime suicidal behavior among adolescents: results from the National Comorbidity Survey Replication Adolescent Supplement. 

 Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. 

 Centers for Disease Control and Prevention. Suicide trends among youths and young adults aged 10-24 years-United States, 1990-2004. 

 Libby AM‚ Brent DA‚ Morrato EH‚ et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. 

 Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. 

 Isacsson G, Ahlner J. Antidepressants and the risk of suicide in young persons-prescription trends and toxicological analyses. 

 Busch SH, Golberstein E, Meara E. The FDA and ABCs: unintended consequences of antidepressant warnings of adolescent human capital. 

Articles

Ten years ago, the FDA placed a black box warning on all antidepressants because of concerns that the medications increase risk of suicidal thoughts and behavior in youths. It's time for the FDA reevaluate that decision.

The Relationship Between Antidepressant Initiation and Suicide Risk

[[{"type":"media","view_mode":"media_crop","fid":"26960","attributes":{"alt":"Dr J. John Mann on suicide prevention","class":"media-image","id":"media_crop_3628522461604","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2575","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]Q&A

Dr J. John Mann, presenter at the U.S. Psychiatric and Mental Health Congress, will be speaking in a symposium titled “Can Science Help the Clinician in Suicide Prevention?”

Q: Why does this topic continue to be important?

 The suicide rate in the US is about the same today as it was in the 1950s. About 40,000 people died by suicide in 2011.

 It is the second leading cause of death in the age group 15 to 34 years. We need to do better at suicide prevention. About 20% of all suicides see a mental health professional within 30 days of their suicide. Most suicides have an untreated mood disorder. We need to improve the diagnosis and treatment of mood disorders.

 In the future, we expect biological tests will supplement clinical risk assessment.

Suicide is not being adequately addressed in terms of prevention, and part of that process is better education of mental health professionals and primary care physicians.

Q: What aspects of this topic do you plan to cover?

stress diathesis model of suicidal behavior

 and explain how prevention involves risk assessment and targeting aspects of both stressors such as an acute episode of major depression and the diathesis which includes mood regulation including pessimism, and reactive aggressive traits or decision-making. The impact on risk of access to lethal means, such as guns and alcohol use, are fundamental considerations in management of risk.

Q: How is this topic relevant to psychiatrists who consider themselves “medication management only” clinicians? 

 Use of antidepressants to treatment major depressive episodes is the single most effective suicide prevention measure in Western countries.

 Even when antidepressants are used, the dose and duration of treatment are frequently inadequate.

Risk reduction in depressed adults is largely determined by the degree of improvement in depression. Psychiatrists and other mental health professionals need to measure the degree of improvement by rating scales in order to optimize treatment response.

Dr Mann’s PsychCongress presentation takes place Monday, September 22, from 10:15 to 11:45 AM.

Dr Mann is The Paul Janssen Professor of Translational Neuroscience (in Psychiatry and in Radiology) at Columbia University and Director, Molecular Imaging and Neuropathology Division at the New York State Psychiatric Institute. He is a Past President of the Society of Biological Psychiatry, the International Academy of Suicide Research and the American Foundation for Suicide Prevention. He is a member of Council and served as Program Chair for the SOBP. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American College of Neuropsychopharmacology.

Dr Mann received his medical degree from the University of Melbourne, and then completed his internship and residency at the Royal Melbourne Hospital. He was trained in Psychiatry and Internal Medicine and has a Doctorate in Neurochemistry. His research employs functional brain imaging, neurochemistry, and molecular genetics to probe the causes of depression and suicide. He has published 596 papers and edited 11 books on the subjects of the biology and treatment of mood disorders, suicidal behavior, and other psychiatric disorders and has been continuously funded by the NIH since 1984. In private practice, he specializes in the treatment of mood disorders and has been repeatedly named as America’s and New York Best Doctors by Castle Connolly.

Dr Mann has received numerous research and teaching awards, including the American Suicide Foundation Research Award, the American Association of Suicidology Louis I. Dublin Award, the New York State Office of Mental Health Research Award, the Klerman Senior Investigator Award from the National Depressive and Manic Depressive Association, the Columbia University Department of Psychiatry Medical Student Teaching Award, the Stengel Award from the International Association for Suicide Prevention, the Morselli Medal from the International Academy of Suicide Research, and the Mood Disorders Research Award from the American College of Psychiatrists.

Dr Mann is an Honorary Professor of the University “Ss. Cyril and Methodius,” Skopje, Macedonia, and received a Visiting Professor Award from the Royal Australian and New Zealand College of Psychiatrists.

1. Centers for Disease Control and Prevention. Suicide and self-inflicted injury. 

http://www.cdc.gov/nchs/fastats/suicide.htm

 Mann JJ, Apter A, Bertolote J, et al. Suicide prevention strategies: a systematic review. JAMA. 2005;294:2064-2074.


 Mann JJ, Currier D, Stanley Bet al. Can biological tests assist prediction of suicide in mood disorders? Int J Neuropsychopharmacol. 2006;9:465-474.


 Heeringen K, Mann JJ. The neurobiology of suicide. 

http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2814%2970220-2/abstract

Suicide is not being adequately addressed in terms of prevention, and part of that process is better education of mental health professionals and primary care physicians. More in this expert Q&A.

Suicide Prevention: Fundamental Considerations

J. John Mann, MD discusses behaviorial indicators and screening instruments for suicide risk. He is speaking at this year's PsychCongress in a presentation titled "Can Science Help the Clinician in Suicide Prevention?"

Dr Mann is Paul Janssen Professor of Translational Neuroscience (in Psychiatry and in Radiology) in the Department of Psychiatry at Columbia University. He is Director of Research and Director of Molecular Imaging and the Neuropathology Division at the New York State Psychiatric Institute in New York. For Part 1 of this 2-part podcast series, 

Podcasts

An expert discusses behavioral indicators and screening instruments for suicide risk.

Suicide Prevention: Detecting High Risk Patients

Dr Mann is Paul Janssen Professor of Translational Neuroscience (in Psychiatry and in Radiology) in the Department of Psychiatry at Columbia University. He is Director of Research and Director of Molecular Imaging and the Neuropathology Division at the New York State Psychiatric Institute in New York. For Part 2 of this 2-part podcast series, 

Advances in Suicide Prevention

[[{"type":"media","view_mode":"media_crop","fid":"26960","attributes":{"alt":"John Mann, MD","class":"media-image","id":"media_crop_6513300881371","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2575","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]By now, most people know that Robin Williams died by suicide, and there probably isn't anyone who is not a Robin Williams fan and admired his wonderful talent. Everybody experiences his loss and death as something personal.

We don't know the details, but it is said that he suffered from a mood disorder and had a problem with alcoholism and struggled against these things for many years. This is not an atypical situation. Mood disorders and suicide affect an astounding number of people from all walks of life.

Here, thoughts on the impact of suicide in general, by Dr John Mann, Paul Janssen Professor of Translational Neuroscience (in Psychiatry and in Radiology) in the Department of Psychiatry at Columbia University. He is Director of Research and Director of Molecular Imaging and the Neuropathology Division at the New York State Psychiatric Institute in New York.

There probably isn't anyone who is not a Robin Williams fan and admired his wonderful talent. Everybody experiences his loss and death as something personal. More in this podcast.

Experiencing the Loss of Robin Williams

Suicide is the third leading cause of death in younger (10- to 14-year-old) adolescents in the United States and the leading cause of death in this age group in other countries, including China, Sweden, Ireland, Australia, and New Zealand.

 The enormous human cost of suicide in youth makes research and prevention a na-tional priority. Biological, psychological, social, and cultural factors all affect the risk of suicide; however, about 90% of youth suicides in the United States are associated with psychiatric illness,

In the general population, there is compelling evidence of lack of continuing treatment for depression. While most of those who complete suicide have sought professional help within one month of death,

 the majority are untreated at the time of death.

 Contrary to recent popular belief, very few children and adolescents who complete suicide are taking medication at the time.

Limited access to care and poor treatment compliance in young patients aggravates the problem. For example, in a study of 49 adolescents who completed suicide in Utah, antidepressants had been prescribed for 24%, but 

tested positive for SSRIs at the time of their death.

 In a postmortem study of 54 youths who completed suicide, only 4 had antidepressants detected on serum toxicological testing within 3 days of death.

Compared with completed suicide (12-month incidence, 8 of 100,000 youths aged 15 to 19 years),

 suicidal thinking and nonfatal attempts are much more common. Based on figures in the 2005 US Youth Risk Behavior Surveillance Report, 19% of teenagers aged 15 to 19 reported suicidal ideation, and 9% of teenagers reported making a suicide attempt during the past year.

 Depression annually occurs in 3% to 5% of youths and accounts for about 60% of suicides for all ages. Our best national estimates reveal that among youths receiving care for depression, 35% to 50% have made, or will make, a suicide attempt,

and 2% to 8% will commit suicide in a decade.

 Thus, treatment of youths who are depressed is an important strategy for preventing suicide.

Over the past few years, warnings have been made about antidepressants potentially causing suicide. In October 2003, the FDA issued a public health advisory for all antidepressants used in treating children and teenagers that cautioned about a potentially higher risk for suicide-attempted and completed. In December 2003, the British Medicines and Healthcare Products Regulatory Agency (MHRA) issued a letter to all doctors advising against the use of almost all antidepressants in anyone younger than 18 years. A similar warning was issued by the European Medicines Agency.

In February 2004, the FDA issued a public health advisory that further cautioned physicians, patients, and families about a possible link between suicide and antidepressants in children and adolescents. In October 2004, the FDA issued a black-box warning for increased suicidality in pediatric patients taking antidepressants, a step just short of banning use in this population. The FDA decision was based on randomized controlled trial (RCT) data suggesting an increase from 2% to 4% in suicidal ideation and behavior when antidepressants, including SSRIs, were prescribed for youths who had not been actively suicidal.

 In December 2006, the FDA convened another meeting of its scientific advisory committee, reviewed its RCT data for adults, and concluded that the black-box warning should be extended to young adults.

A major limitation of these studies is that no suicides were reported in the pediatric studies for either placebo or active medication, and only 8 completed suicides were reported in the adult studies, with no significant differences by condition (placebo, 2 of 36,049; test drug, 5 of 53,030; active control, 1 of 11,217). Also, the RCTs reviewed by the FDA excluded youths who had recently thought about or attempted suicide. As such, even the combination of the 372 studies and close to 100,000 patients provided little or no evidence about the effects of antidepressants on completed suicide.

Others have noted that the finding of increased suicidality in youths treated with antidepressants was limited to medical record data; there was no difference in suicidality obtained from standardized questionnaires.

In a recent reanalysis of the FDA data, augmented by additional studies that have become available since 2004, the difference between antidepressants and placebo in suicidal ideation (abstracted from medical records) was no longer statistically significant, whereas a pooled analysis of clinical response rates found a statistically significant beneficial effect for anxiety disorders and depression in children and adolescents that was not confined to any one antidepressant.

 The result of this study is that antidepressants do show evidence of an antidepressant effect in the pediatric population and that the risk of nonfatal suicidal acts or suicidal ideation is less than that estimated by the FDA in its earlier analyses, yielding a clearly positive benefit-to-risk ratio.

The FDA's findings for children appear to be inconsistent with psychological autopsy studies of completed suicide that suggest very few pediatric suicides were associated with SSRIs.

 They also are inconsistent with ecological studies on suicide completion

and attempts that indicate an overall protective effect of SSRIs in pediatric and young adult populations.

 found a significant inverse relationship between county-level SSRI prescription levels and adult suicide rates both within counties over time and between counties. This is consistent with a protective effect of SSRIs, both in the overall population and in a specific analysis of 5- to 14-year-olds in the United States.

 demonstrated an inverse association between SSRI prescription rates and SSRIs from 1980 to 1999 in 26 European countries; similar results have been found in the United States.

 confirmed a significant inverse association between SSRI sales and suicide rates from 1980 to 2004 in a county-level analysis in Norway. Isacsson

 hypothesized that an increase in antidepressant prescriptions in Sweden would be associated with a reduction in suicides. As a natural experiment, he found that a 3.5-fold increase in antidepressant prescriptions in Sweden over time was associated with a 19% decrease in suicides.

The FDA has recently extended the black-box warning to young adults aged 18 to 24 years based on a meta-analysis of RCTs

 that showed increased rates of suicidal ideation in young adults under 25 years, but either no effects or protective effects in adults older than 25. However, Gibbons and colleagues

 showed that in a comparison of 18- to 25-year-olds who were treated with an SSRI alone versus those who had no antidepressant therapy, there was one third the risk of a serious suicide attempt in the treated group (odds ratio, 0.35; confidence interval, 0.14 to 0.85; 

 < .021). In this age group, treatment with an SSRI alone produced a 57% decrease in suicide attempts relative to the same young adult age group before antidepressant treatment was initiated.

Similar protective effects of antidepressant treatment were found for adults who were older than 25 years. The findings revealed that when active treatment was compared with no treatment rather than a placebo control condition, and the patients were not excluded on the basis of having preexisting suicidal behavior, antidepressants had a protective effect on suicidal behavior in both younger and older adult populations. Simon and Savarino

 have also shown that both antidepressant therapy and psychotherapy significantly reduce the risk of attempted suicide in the general population as well as in young adults aged 18 to 24 years.

Taken as a whole, these ecological data on suicide rates suggest that decreases in newer antidepressant prescriptions (SSRIs and serotonin-norepinephrine reuptake inhibitors [SNRIs]), in response to the FDA warnings, will lead to increases in the suicide rate. Unfortunately, just such a natural experiment has taken place. Between 2003 and 2005, SSRI prescription rates decreased by approximately 20% in children in the United States in response to public health advisories from the FDA and the MHRA in the United Kingdom as well as the 2004 FDA black-box warning (

 Smaller decreases have also been observed in SSRI prescription rates in adults younger than 60 years.	

Suicide rate data published by the CDC have recently been released for 2004.

 In youths (aged 5 to 19 years), there was a 14% increase in suicide rates from 2003 to 2004 (2.83 of 100,000 vs 3.23 of 100,000, 

 < .0001). Except for minor fluctuations in 1994 (1% increase) and in 2000 (3% increase), there had been a consistent reduction in youth suicide rates from 4.4 of 100,000 in 1988 to 2.83 of 100,000 in 2003 (

). If SSRIs were causing suicides in the general population, we would expect the reverse. In contrast to these results for youth, it was noted that at the same time prescription rates continued to rise for adults older than 60 years and their suicide rates continued to fall.

 In Europe, similar findings have been reported for SSRI prescription and suicide rates in youths.

Furthermore, the treatment as well as the diagnosis of childhood depression also decreased since the black-box warning took effect.

 Based on predictions from preadvisory data, SSRI prescriptions are 58% lower than predicted (had the warnings not taken place) and the rate of diagnosis of major depressive disorder by both pediatricians and primary care physicians is 32% lower.

 These reductions in antidepressant treatment and diagnosis of depression have "spilled over" to the adult population where significant decreases in the percentage of adults with new depressive episodes have been observed since the black-box warning was released.

In addition, the investigators found that there was a significant increase in the percentage of depressed adult patients who did not receive antidepressant treatment (from 20% before the black-box warning to 30% after the black-box warning).

 These findings fill in an intermediate step related to the observed decrease in antidepressant prescriptions, namely a decreased rate of diagnosis of new episodes of depression in both pediatric and adult populations.

The findings of this natural experiment support the hypothesis that the effect of the black-box warning has been to lower antidepressant prescription rates, which in turn has resulted in more untreated depression and a corresponding increase in suicide rates for children and adolescents.

 The FDA sought to improve treatment of depression, but an overall decline in diagnosis and treatment of depression implies that the black-box warning did not achieve this goal, and the decline is consistent with the possibility that the black-box warning has had the opposite effect.

Although unintended, the FDA's black-box warning has led to a decrease in the pharmacological treatment of pediatric depression and a decrease in the diagnosis of pediatric depression. At the same time, we have seen the largest increase in child, adolescent, and teen suicide since the CDC began recording these data in 1979. In the event that these results are further confirmed by 2005 suicide rate data, it becomes clear that the black-box warning should be reconsidered and replaced by an effort to improve diagnosis of major depression, improved access to treatment, and more careful monitoring of treatment with antidepressants where indicated.

A black-box warning has only been rescinded once in history, for the drug omeprazole in 2003, but given the mortality of youth suicide and the need to reverse these alarming trends and loss of life, such a step may prove necessary for antidepressant labeling in children and young adults.

 Goldsmith SK, Pellmar TC, Kleinman AM, Bunney WE. 

 Washington, DC: The National Academies Press; 2002:1-516.


 Brent DA, Perper JA, Goldstein CE, et al. Risk factors for adolescent suicide: a comparison of adolescent suicide victims with suicidal inpatients. 

 Shaffer D. Suicide: risk factors and the public health. 

 Barraclough B, Bunch J, Nelson B, Sainsbury P. One hundred cases of suicide: clinical aspects. 

 Robins E, Murphy GE, Wilkinson RH Jr, et al. Some clinical considerations in the prevention of suicide based on a study of 134 successful suicides. 

 Rich CL, Fowler RC, Fogarty LA, Young D. San Diego suicide study, III: relationships between diagnoses and stressors. 

 Dorpat TL, Ripley HS. A study of suicide in the Seattle area. 

 Isometsä E, Henriksson M, Marttunen M, et al. Mental disorders in young and middle aged men who commit suicide. 

 Beautrais AL, Joyce PR, Mulder RT, et al. Prevalence and comorbidity of mental disorders in persons making serious suicide attempts: a case-control study. 

 Isacsson G, Boëthius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. 

 Isacsson G, Holmgren P, Druid H, Bergman U. The utilization of antidepressants--a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994. 

 Oquendo MA, Malone KM, Ellis SP, et al. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. 

 Isometsä E, Henriksson M, Heikkinen M, et al. Suicide and the use of antidepressants: drug treatment of depression is inadequate. 

 Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide: a review of the evidence. 

 Leon AC, Marzuk PM, Tardiff K, Teres JJ. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. 

 Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. 

 Gray D, Moskos M, Keller T. Utah Youth Suicide Study New Findings. Presented at: the annual meeting of the American Association of Suicidology; 2003; Sante Fe, NM.


 Anderson RN. Deaths: leading causes for 2000. 

 Grunbaum JA, Kann L, Kinchen SA, et al. Youth risk behavior surveillance-United States, 2001. 